Expert Interview
Looking at Regenxbio's Phase II Study of Subretinal ABBV-RGX-314 in Patients with Bilateral Wet AMD
Ticker(s): RGNX, FDMT, ABBV, RHHBY, REGNInstitution: Medical Center Ophthalmology Associates
- Director of Clinical Research at Medical Center Ophthalmology Associates in San Antonio, TX and Clinical Professor of Ophthalmology at University of Texas Health Science San Antonio.
- Treats 400 patients with wet AMD and Diabetic Macular Edema
- Clinical and research interests primarily focuses on macular degeneration and diabetic retinopathy, retinal detachment and retinal vein occlusion.
- Has participated in over 150 clinical trials and presented research nationally and internationally.
Please describe your practice as a clinician: how many patients with wet AMD do you treat on a yearly basis?
Could you walk us through the standard of care, and tell us a bit about the most promising upcoming treatments, or interesting clinical trials in this space.
What is your opinion on the potential of gene therapies for wet-AMD patients?
What is your view on the route of administration for ABBV-RGX-314?
Added By: ben_adminWill the cost of gene therapies be a big barrier for wet-amd adoption?
Added By: ben_adminRank your excitement for ABBV-RGX-314 on a scale of 1-10?
Added By: ben_adminWould you suggest any novel endpoints in the Phase 3 program, such as reduction in VEGF use? Any other endpoints based on potential payer responses?
Added By: user1b6ba135Do you have a patient profile in mind for who would be an ideal candidate for gene therapy? How much do you think prior authorizations and other payer tactics will interfere with access for these patients?
Added By: user1b6ba135Please ask about VEGF TKIs and the OPT VEGF-C/D trap if you have time.
Added By: joe_mccannWhat long term safety data would you like to see collected in Phase 3, LTEs or REMS studies?
Added By: user1b6ba135Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
